Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of gemcitabine + carboplatin with or without iniparib in untreated stage IV squamous NSCLC
NL-OMON39236Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- May 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Pulmonary squamous cell carcinoma comparing Gemcitabine + carboplatin + iniparib with Gemcitabine + carboplatin (2 arms). Primary endpoint: overall survival. Started May 2011; status: active, not recruiting.
02
Drugs
iniparibgemcitabinecarboplatin
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on NL-OMON39236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39236.